Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from GH Research ( (GHRS) ).
GH Research PLC announced the acceptance of posters related to its GH001-TRD-201 clinical trial at the upcoming 64th American College of Neuropsychopharmacology annual meeting in January 2026. The trial results indicate that GH001, a synthetic form of mebufotenin, shows promise in reducing depressive symptoms without increasing the risk of suicidal ideation or behavior in patients with treatment-resistant depression, potentially enhancing the company’s position in the mental health treatment market.
The most recent analyst rating on (GHRS) stock is a Buy with a $19.00 price target. To see the full list of analyst forecasts on GH Research stock, see the GHRS Stock Forecast page.
Spark’s Take on GHRS Stock
According to Spark, TipRanks’ AI Analyst, GHRS is a Neutral.
GH Research’s stock score reflects significant challenges in financial performance, with consistent losses and negative cash flows. The company’s strong equity base and low debt provide some stability. Technical indicators show some short-term momentum, but valuation concerns persist due to the negative P/E ratio and lack of profitability.
To see Spark’s full report on GHRS stock, click here.
More about GH Research
GH Research PLC is a company operating in the pharmaceutical industry, focusing on developing innovative treatments for mental health disorders. Their primary product, GH001, is a synthetic form of mebufotenin designed for pulmonary inhalation, targeting treatment-resistant depression and bipolar II disorder.
Average Trading Volume: 317,262
Technical Sentiment Signal: Strong Buy
Current Market Cap: $857.2M
See more insights into GHRS stock on TipRanks’ Stock Analysis page.